Huichun Su

Dr. Huichun Su

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Indian Journal of Dermatology, Venereology and Leprology
Verified
Journal Article
Open access
YZYaxuan Zheng
Yaxuan Zheng
YHYue Han
Yue Han
JCJincong Chen
Jincong Chen
JHJiahao Huang
Jiahao Huang
CZChanghua Zhu
Changhua Zhu
HSHuichun Su
Huichun Su
Background Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors are novel treatments for moderate-to-severe plaque psoriasis. Objective To perform a network meta-analysis to compare the efficacy and safety of TYK2 inhibitors with other oral drugs in moderate-to-severe psoriasis. Methods Eligible randomised clinical trials (RCTs) were identified from public databases (published before November 2, 2023). Random-effect frequentist network meta-analysis was performed with ranking based on the surface under the cumulative ranking curve (SUCRA) of Physician’s Global Assessment of “clear” or “almost clear” (PGA 0/1), 75% reduction from baseline in Psoriasis Area and Severity Index (PASI-75). Results Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included. Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12– 16 weeks. Tofacitinib (10 mg BID) was considered the most unsafe. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Limitations Insufficiency of eligible data and no long-term follow-up data. Conclusion Deucravacitinib showed superior efficacy and safety for treating moderate-to-severe psoriasis over other included drugs.

24 February 2025 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
CZChanghua Zhu
Changhua Zhu
YZYaxuan Zheng
Yaxuan Zheng
LLLianming Liao
Lianming Liao
JCJincong Chen
Jincong Chen
LLLihang Lin
Lihang Lin
HSHuichun Su
Huichun Su

19 August 2024 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
YZYaxuan Zheng
Yaxuan Zheng
MLMin Luo
Min Luo
JHJiahao Huang
Jiahao Huang
MMMarcus Maurer
Marcus Maurer
HSHuichun Su
Huichun Su

12 December 2023 in The Journal of Dermatology
Verified
Journal Article
Closed access
JCJincong Chen
Jincong Chen
YZYaxuan Zheng
Yaxuan Zheng
CZChanghua Zhu
Changhua Zhu
LLLihang Lin
Lihang Lin
HSHuichun Su
Huichun Su